Wednesday, April 5, 2017

Alzheimer’s: ultrasound safely delivers drugs to damaged brains of mice

A brain with probable Alzheimer’s disease (right, compared to normal brain on left) can safely reached with ultrasound. Photograph: BSIP/UIG via Getty Images

Scientists at Queensland Brain Institute find noninvasive technique slows progression of Alzheimer’s disease in mice

Australian researchers say they have made a promising step in the future treatment of Alzheimer’s disease after discovering ultrasound can effectively and safely deliver drugs to the damaged brain.

Scientists at the Queensland Brain Institute found the noninvasive technique successfully penetrated the blood-brain barrier to deliver a therapeutic antibody to the brain. This then slowed the progression of Alzheimer’s disease in mice, according to a study published in the journal Brain.

Scientists at the Queensland Brain Institute found the noninvasive technique successfully penetrated the blood-brain barrier to deliver a therapeutic antibody to the brain. This then slowed the progression of Alzheimer’s disease in mice, according to a study published in the journal Brain.

One of the major challenges inhibiting the treatment of Alzheimer’s is that the majority of drugs designed to treat the brain disease do not make it into the brain.

“Ultrasound safely opens up the blood-brain barrier just a tiny bit and just for short time to let the antibody into the brain and, importantly, into the nerve cells where the damage occurs,” said Prof Jurgen Gotz, the lead researcher at QBI.

Alzheimer’s disease is the most common form of dementia, with the number of dementia cases in Australia expected to rise to 900,000 by 2050.

Using scanning ultrasound technology, researchers at QBI delivered an antibody that specifically binds to a protein called tau implicated in the progression of Alzheimer’s.

Combining ultrasound with the antibody treatment is more effective than either treatment alone in removing the toxic protein clumps, say the researchers. “We ultimately hope in the coming years to develop an ultrasound device that is not too bulky and can also be used to treat local patients,” Gotz said. “This device may clear toxic tau in patients on its own or it may be used by delivering therapeutic agents such as drugs or antibodies.”

The lead author of the study, Dr Rebecca Nisbet, said this would have enormous benefits by making expensive treatment more cost-effective. “You’re increasing the amount of therapeutic agents that can enter the brain, thereby reducing the number of a doses and the amount that needs to be delivered,” she said.

Story Source: The above story is based on materials provided by THEGUARDIAN

Note: Materials may be edited for content and length

Click here to read more